As a diversified fund, we invest in both technology and life sciences opportunities. In the life sciences, we are active in these areas.
OTD currently holds positions in the following representative companies: |
Adipogenix
(BU company)
Developing pharmaceuticals that treat obesity based on technology developed by Dr. Barbara Corkey at BU. |
 |
Afferent
(BU Company):
Medical device company focused on treating neurologic dysfunction. The technology is based on the work of Dr. Jim Collins at BU. |
 |
Cellicon Biotechnologies
(BU Company):
Developing novel anti-infective drug targets and compounds using its unique Systems Biology platform developed by Dr. Jim Collins at BU. |
 |
Elixir, Inc.
Drug discovery based on the genetics and signal transduction underlying age-related illnesses |
 |
Infinity Pharmaceuticals
Laboratory synthesis of new chemical entities with unprecedented structural diversity |
 |
MicroCHIPS, Inc.
Implantable, microchip-based drug delivery and biosensory systems |
 |
Modular Genetics
(BU Company)
The company's technology, CombiGenix TM, is a universal system used for designing and creating large sets of engineered genes. |
 |
Ophthonix
Developer of iZonTM high resolution lenses. |
|
SelectX Pharmaceuticals
New chemical entities produced by cloned biosynthetic pathways |
 |
Previous Investments: |
Acusphere, Inc.
Contrast agents for ultrasound imaging applications.
IPO: 2003 (NASDAQ: ACUS) |
 |
AtheroGenics, Inc.
Therapeutic treatment of atherosclerosis and other diseases.
IPO: 2000 (NASDAQ: AGIX) |
 |
Cynosure, Inc.
Medical devices for cosmetic laser surgery. Acquired by Italian company El. En. S. p. A. in May 2002. |
 |
Exact Sciences, Inc.
Non-invasive diagnostic for early detection of colorectal cancer.
IPO: 2001 (NASDAQ: EXAS) |
 |
Insmed Pharmaceuticals, Inc.
Therapeutic treatment of diabetes and metabolic disorders..
IPO: 2000 (NASDAQ: INSM) |
 |
Ligand, Inc.
Fusion proteins for treatment of cancer, psoriasis, and other diseases.
Seragen IPO: 1992 (NASDAQ:SRGN)
Acquired by: Ligand Pharmaceuticals Inc. 1998 (NASDAQ:LGND) |
 |
Myriad Genetics, Inc.
Genomics-based drug delivery and diagnostics.
IPO: 1995 (NASDAQ: MYGN) |
 |
NitroMed, Inc.
Nitric oxide enhanced medicines IPO: 2003 (NASDAQ: NTMD) |
 |
Peer Review Analysis, Inc.
Health-benefits management services.
IPO: 1991 (NASDAQ:PRAI)
Acquired by: Core, Inc 1995 (NASDAQ:CORE) |
 |
Sequenom, Inc.
DNA analysis tools and systems..
IPO: 2000 (NASDAQ:SQNM) |
 |
Summit Technology, Inc.
Ophthalmic laser systems.
IPO: 1998 (NASDAQ: BEAM) |
 |
Vista Medical Technologies, Inc.
Visualization systems for minimally invasive surgery.
IPO: 1997 (NASDAQ: VMTI) |
 |
Visualization Technology, Inc.
Image-guided surgery systems. Acquired by General Electric (NYSE: GE) in April 2002. |
 |
